Over the last 7 days, the United States market has risen 1.6% and in the past year, it has climbed 19%, with earnings expected to grow by 18% per annum in the coming years. In such a dynamic environment, identifying high growth tech stocks involves looking at companies that demonstrate strong innovation potential and robust financial health to capitalize on these favorable conditions.
Top 10 High Growth Tech Companies In The United States
| Name | Revenue Growth | Earnings Growth | Growth Rating |
|---|---|---|---|
| AppLovin | 21.15% | 21.76% | ★★★★★★ |
| Krystal Biotech | 29.15% | 36.59% | ★★★★★★ |
| 21.88% | 25.35% | ★★★★★★ | |
| Fabrinet | 21.38% | 23.34% | ★★★★★★ |
| Sandisk | 46.18% | 46.18% | ★★★★★★ |
| Palantir Technologies | 30.88% | 31.93% | ★★★★★★ |
| Zscaler | 14.32% | 55.01% | ★★★★★☆ |
| Tenaya Therapeutics | 59.68% | 60.87% | ★★★★★☆ |
| Circle Internet Group | 21.37% | 48.68% | ★★★★★☆ |
| Duos Technologies Group | 61.81% | 48.23% | ★★★★★☆ |
Click here to see the full list of 60 stocks from our US High Growth Tech and AI Stocks screener.
Below we spotlight a couple of our favorites from our exclusive screener.
ADMA Biologics (ADMA)
Simply Wall St Growth Rating: ★★★★☆☆
Overview: ADMA Biologics, Inc. is a biopharmaceutical company that focuses on developing, manufacturing, and marketing specialty plasma-derived biologics for treating immune deficiencies and infectious diseases globally, with a market cap of approximately $2.07 billion.
Operations: ADMA Biologics generates revenue primarily through its ADMA Biomanufacturing segment, contributing $493.03 million, and its Plasma Collection Centers, which add $16.70 million.
ADMA Biologics recently joined the Russell 2000 Defensive and Growth-Defensive Indexes, signaling an increased market recognition amidst a challenging phase marked by a class-action lawsuit over alleged misleading statements and inadequate internal controls. Despite these hurdles, ADMA reported a robust Q1 with earnings rising to $45.33 million from last year's $26.9 million, reflecting strong operational execution with sales slightly down at $114.49 million from $114.8 million previously. The company has also been proactive in shareholder returns, repurchasing 6.75 million shares for $130.28 million in early 2026 under its ongoing buyback program, highlighting confidence in its financial health and future prospects.
- Click to explore a detailed breakdown of our findings in ADMA Biologics' health report.
Understand ADMA Biologics' track record by examining our Past report.
RUM Group (RUM)
Simply Wall St Growth Rating: ★★★★★☆
Overview: RUM Group Inc. operates as a video sharing and cloud services platform across the United States, Canada, and internationally with a market capitalization of approximately $2.09 billion.
Operations: RUM Group generates revenue primarily from its Internet Software & Services segment, amounting to $102.38 million. The company focuses on providing video sharing and cloud services across multiple regions.
Despite recent setbacks, including being dropped from multiple Russell indexes, RUM Group has demonstrated resilience and strategic agility. The company's revenue growth is impressive at 60% annually, outpacing the US market average of 12.7%. This growth is bolstered by significant developments such as the multi-year agreement with Together AI for dedicated GPU cloud capacity, which not only enhances RUM's service offerings but also positions it as a formidable player in AI infrastructure provision outside traditional ecosystems. Furthermore, with earnings expected to surge by approximately 93.74% annually, RUM Group is setting a robust trajectory for profitability and market impact within the tech sector.
- Unlock comprehensive insights into our analysis of RUM Group stock in this health report.
Gain insights into RUM Group's historical performance by reviewing our past performance report.
Sprinklr (CXM)
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Sprinklr, Inc. offers enterprise cloud software solutions globally and has a market capitalization of approximately $1.27 billion.
Operations: The company generates revenue primarily from its software and programming segment, which accounted for $871.18 million. With a focus on enterprise cloud solutions, it operates on a global scale.
Sprinklr's recent inclusion in multiple Russell indexes underscores its growing influence in the tech sector, particularly with its innovative AI-driven solutions like LLM Insights. This tool not only enhances brand visibility across AI-generated content but also offers actionable insights, setting Sprinklr apart in a competitive landscape. The appointment of Thomas Addis as Chief Revenue Officer, known for his role in scaling revenues at Bazaarvoice and Box through strategic leadership, signals Sprinklr's commitment to sustained growth. Moreover, the successful repurchase of shares worth $125 million reflects confidence in its financial strategy and future prospects.
- Navigate through the intricacies of Sprinklr with our comprehensive health report here.
Evaluate Sprinklr's historical performance by accessing our past performance report.
Next Steps
- Discover the full array of 60 US High Growth Tech and AI Stocks right here.
- Have a stake in these businesses? Integrate your holdings into Simply Wall St's portfolio for notifications and detailed stock reports.
- Streamline your investment strategy with Simply Wall St's app for free and benefit from extensive research on stocks across all corners of the world.
Curious About Other Options?
- Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
- Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
- Find companies with promising cash flow potential yet trading below their fair value.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com